Sort
82,697 grants matching “vaccine development”
Psoralen-Killed, Metabolically-Active Anthrax Vaccine
$1,174,248Cerus Corporation · U01 · FY2005 · AI
Center for Molecular, Cellular, and Translational Immunology
$1,174,198William R Green · Dartmouth College · P30 · FY2015 · GM
Preclinical development of a TriCoil-based nicotine vaccine
$1,174,182Christopher H Clegg · Tria Bioscience Corporation · UH2 · FY2015 · DA
Addressing COVID-19 Testing Disparities in Vulnerable Populations Using a Community JITAI (Just in Time Adaptive Intervention) Approach - Phase II
$1,174,131David D McPherson · University Of Texas Hlth Sci Ctr Houston · UL1 · FY2021 · TR
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
$1,173,856Barry Coller · Rockefeller University · UL1 · FY2009 · RR
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
$1,173,855Barry Coller · Rockefeller University · UL1 · FY2009 · RR
Model-guided design of RNA stabilizing elements for improved coronavirus diagnostics
$1,173,739Xiao Wang · Arizona State University-Tempe Campus · R01 · FY2021 · EB
Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit
$1,173,611Margaret A Fischl · University Of Miami School Of Medicine · UM1 · FY2012 · AI
Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure
$1,173,561Sharon Riddler · University Of Pittsburgh At Pittsburgh · U01 · FY2020 · AI
Vaccine Clinical Trials
$1,173,524Philip M Arlen · Basic Sciences · Z01 · FY2007 · CA
Vaccine Clinical Trials
$1,173,524James L. Gulley · Basic Sciences · Z01 · FY2007 · CA
Modulation of Biodefense Responses to Bacterial Pathogen
$1,173,511University Of Connecticut Sch Of Med/Dnt · P01 · FY2004 · AI
PREVENTION OF MATERNAL AND CONGENITAL CMV INFECTION
$1,173,358University Of Alabama At Birmingham · P01 · FY2002 · AI
Primate Core
$1,173,241Roger A Van Andel · University Of New Mexico · P01 · FY2007 · AI
Immune Regulation in Mycobacterial and Fungal Infections
$1,173,111Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Structure-based design of novel Lassa virus glycoproteins for vaccine development
$1,172,924Robert F Garry · Tulane University Of Louisiana · R01 · FY2021 · AI
SASEA
$1,172,864Rebecca Kathleen Fielding-Miller · University Of California, San Diego · U01 · FY2022 · HD
Predicting immune responses that correlate with protection against tuberculosis
$1,172,751Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2013 · HL
Bacteriophage-based approach for managing Shigella infections
$1,172,622Alexander Sulakvelidze · Intralytix, Inc. · U01 · FY2023 · AI
Herpesvirus Pathogenesis and Vaccine Development
$1,172,211Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Protective and pathogenic B cell epitopes in Francisella tularensis
$1,171,978Jacqueline Sharon · Boston University (Charles River Campus) · N01 · FY2013 · AI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
$1,171,930Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2020 · AI
Influenza Modeling of Correlates of Protection for Optimal Immune Dynamics and Evolution.
$1,171,832Rafael A. Medina Silva · Emory University · U01 · FY2025 · AI
Bacteriophage-based approach for managing Shigella infections
$1,171,611Alexander Sulakvelidze · Intralytix, Inc. · U01 · FY2022 · AI
Comparative Modeling to Inform Cervical Cancer Control Policies
$1,171,441Jane Jooyun Kim · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2024 · CA